A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up.
Case 3 A 32-year-old white man underwent LT in January 2009 because of HCV-related cirrhosis. HIV infection was diagnosed in 2004, with a nadir CD4 cell count of 0.347 10/L (347/KL) (stage A2). ART was started in 2005 with a cumulative exposure of 2 months to PIs. The patient was a smoker and is overweight. IS therapy was based on rapamycin and methylprednisolone (cumulative dose of 1880 mg). The same pretransplant ART regimen containing lamivudine, raltegravir, and unboosted atazanavir was resumed on the 10th pod. Two months after transplantation, rapamycin was switched to cyclosporine because of painful peripheral edemas. In April 2009, he reported an intense left coxalgia. MRI revealed bilateral ON in the femoral heads (Fig. 1D), which was then confirmed by positron emission tomography. For inefficacy of conservative treatment, in July 2009, total hip arthroplasty on the left side was performed. To date, indication for contralateral hip replacement has not yet been placed.